9 results about "Human keratinocyte" patented technology

A method of immortalizing a human keratinocyte. Also provided are immortalized human keratinocytes, for example immortalized human keratinocytes that have been immortalized using the presently disclosed method. Further provided are organotypic cultures, co-cultures, assays and kits comprising one or more immortalized human keratinocytes. In one embodiment, the immortalized human keratinocyte is produced by sequentially deleting the p16 locus, using CRISPR-Cas9 based gene editing, followed by lentiviral-based introduction of the gene encoding human telomerase reverse transcriptase (hTERT).

The present invention relates to ex vivo methods for obtaining populations of human keratinocytes derived from human pluripotent stem cells (hPSCs).More particularly, the present invention relates to an automated method that combines in a sequential manner automated differentiation and amplification of a population of hPSC-derived keratinocytes.

The invention belongs to the technical field of gene engineering, and discloses recombinant human fibronectin as well as a preparation method and application thereof. The amino acid sequence of the recombinant human fibronectin disclosed by the invention is as shown in SEQ ID NO. 1. The recombinant human fibronectin comprises three fragments which are derived from natural fibronectin and have high hydrophilicity and multiple integrin binding capacity, the fragments are expressed in escherichia coli, and the recombinant human fibronectin with high soluble expression quantity is obtained; the recombinant human fibronectin has high activity of promoting proliferation and migration of human keratinocytes, and has potential application prospects in the aspects of skin repair and wound healing.

The invention provides an HPV (human papillomavirus) infected human epidermal keratinocyte model and a construction method and application thereof, and relates to the technical field of molecular biology, an HPV genome is integrated to a KRT5 site of genome DNA (deoxyribonucleic acid) of human epidermal keratinocytes to obtain the HPV infected human keratinocyte model, stable integration and expression of an HPV whole genome are successfully realized, and the HPV infected human keratinocyte model is obtained. The position effect caused by random insertion is avoided, and the genetic stability is ensured; the model has the synergistic expression function of HPV early and late genes, maintains the time sequence of virus gene expression, realizes HPV virus particle assembly, and simulates the complete life cycle of HPV. The technical problem that in the prior art, an infection model cannot simulate the complete life cycle of the HPV is solved.

This invention provides a stem cell preparation for skin repair and its application, belonging to the field of biomedical technology. The stem cell preparation is obtained by inducing stem cells in a composite culture medium containing sodium butyrate, L-carnosine, and quercetin, followed by short-term pulsed hypoxia treatment, ultrasonic disruption, deep freeze-thaw rehydration, and vacuum freeze-drying to obtain a lyophilized stem cell powder. Experimental results show that the stem cell preparation of this invention significantly promotes the proliferation of human skin fibroblasts and significantly promotes the migration of human keratinocytes. In a mouse full-thickness skin defect model, local application after reconstitution in PBS buffer containing 0.1% sodium hyaluronate (concentration ≥100 μg / mL) significantly accelerates wound closure. In summary, the preparation of this invention exhibits high activity, strong stability, and broad prospects for clinical translation.

This invention discloses the application of METTL14 inhibitors in the preparation of drugs for the prevention and treatment of skin injuries. This invention also reveals for the first time the downregulation of METTL14 in human keratinocytes (HaCaT cells), human skin fibroblasts (WS1 cells), and animal tissues by ultraviolet B (UVB) radiation. 6 The downregulation of METTL14 protein levels, mediated by the reduction of METTL14 expression, can treat skin damage, providing a new approach for developing interventional targets for drugs treating UV-induced skin radiation damage.

This invention discloses a method for predicting and validating the comprehensive skin toxicity of daily-use preservatives based on multi-pathway responses in keratinocyte-fibroblast co-culture, belonging to the technical field of daily chemical safety evaluation. This invention uses human keratinocytes (HaCaT) and human dermal fibroblasts (HSF) as dual targets, and assesses the mechanistic skin toxicity of preservatives through multiple endpoints including inflammation, barrier damage, cell senescence, and organelle damage, classifying them and guiding their formulation application. The method of this invention boasts high prediction accuracy, high sensitivity, high efficiency, and compliance with regulations. It overcomes the limitations of traditional methods that only focus on "cell viability," providing a panoramic analysis of the toxic action pathways of preservatives from three dimensions: gene expression (early signal), organelle damage (intermediate process), and population apoptosis (final outcome), avoiding false negatives caused by single endpoints and possessing broad application prospects.

ANTI-AGING SKINCARE COMPOSITION The invention relates to a skincare composition comprising a plurality of agents, each including at least one retinol derivative and at least one bark extract. The plurality of agents provides reduced retinol-associated inflammation compared to a composition that includes at least one retinol but lacks at least one bark extract. The plurality of agents may include at least one retinol derivative comprising hydroxypinacolone retinoate and at least one bark extract, which may include at least one bark extract comprising an extract of Eperua falcata bark. The plurality of agents may also include at least one hydroxy acid, for example, comprising lactic acid. The composition confers one or more of the following: increased skin cell proliferation, improved cell migration, improved cell differentiation, or a combination thereof.The application of multiple agents confers an anti-inflammatory retinol genetic signature to skin cells and tissues, as demonstrated by bulk RNA sequencing of human keratinocytes, and restores epidermal disruption and reduces the inflammatory cytokines IL-1A and IL-23 in ex vivo human skin models of chronic inflammation. Figure for abstract: none.

Systems and methods for measuring cell senescence are provided herein.